The company will not receive any proceeds from the sale of the ordinary shares by the selling shareholder.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALVO:
- Alvotech Reports Revenue Surge Amidst Expansion
- Alvotech’s Biosimilar AVT06 Eyes European Market
- European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
- Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET
- Alvotech price target lowered to $18 from $22 at Barclays
Questions or Comments about the article? Write to editor@tipranks.com